UAE Insulin Delivery Devices Market Industry Size, Share, Trends, Opportunity, and Forecast Segmented By Product Type (Pens {Disposable, Reusable}, Pumps {External/Tethered Pumps, Patch Pumps}, Pen Needles {Standard Pen Needles, Safety Pen Needles), Others) By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online, Others) By End User (Hospitals & Clinics, Homecare, Others), by region, and Competition 2021-2031F

Forecast Period	2027-2031
Market Size (2025)	USD 110.18 Million
CAGR (2026-2031)	8.11%
Fastest Growing Segment	Homecare
Largest Market	Abu Dhabi
Market Size (2031)	USD 175.91 Million

Market Overview

The UAE Insulin Delivery Devices Market will grow from USD 110.18 Million in 2025 to USD 175.91 Million by 2031 at a 8.11% CAGR. Insulin delivery devices are specialized medical instruments, comprising syringes, insulin pens, pumps, and jet injectors, designed to administer insulin subcutaneously for the management of diabetes mellitus. The market in the United Arab Emirates is primarily driven by the critically high incidence of lifestyle-related diabetes and an expanding geriatric population that necessitates consistent glycemic control. Furthermore, substantial government investment in healthcare infrastructure and proactive national screening initiatives significantly improve diagnosis rates, thereby creating a sustained fundamental demand for reliable insulin administration solutions.

Despite these favorable drivers, the market encounters a significant challenge regarding patient adherence, often stemming from needle phobia and the discomfort associated with daily injections. This psychological barrier can delay the initiation of necessary insulin therapy and impede the adoption of conventional delivery systems, limiting the effective utilization of these devices. The scale of the addressable market is substantial; according to the International Diabetes Federation, in 2025, the diabetes prevalence among adults in the United Arab Emirates was reported to be 20.7%.

Key Market Drivers

The Escalating Prevalence of Type 1 and Type 2 Diabetes is the primary force stimulating the UAE insulin delivery devices market, creating an urgent requirement for advanced therapeutic interventions. This rising burden is amplified by lifestyle factors, leading to a substantial population requiring lifelong insulin dependency. According to Khalifa University, November 2024, projections indicate that approximately 1.6 million residents in the UAE could be living with Type 2 diabetes by 2031. This expected increase necessitates a parallel expansion in user-friendly devices, such as pens and pumps, to manage the condition effectively. The market is further influenced by underlying health trends; according to the Ministry of Health and Prevention, January 2024, the obesity rate among adults reached 27.8%, a statistic that directly correlates with the growing pool of patients susceptible to metabolic disorders.

Increasing Healthcare Expenditure and Robust Insurance Mandates function as a critical secondary driver, ensuring financial access to necessary medical technologies. The national commitment is reflected in budgetary enhancements that subsidize costs and improve infrastructure for chronic disease management. According to the UAE Government, October 2024, the federal budget for 2025 allocated AED 5.745 billion to healthcare and community prevention services. This investment enables public facilities to procure modern insulin systems and supports insurance frameworks that reduce out-of-pocket burdens for patients. Consequently, these financial mandates lower adoption barriers, encouraging the widespread utilization of effective administration devices across the Emirates.

Download Free Sample Report

Key Market Challenges

Patient adherence issues, primarily stemming from needle phobia and the physical discomfort of daily injections, constitute a significant restraint on the UAE Insulin Delivery Devices Market. This psychological resistance frequently leads to "psychological insulin resistance," where patients delay or refuse the initiation of necessary insulin therapy in favor of oral medications, even when the latter are less effective for their condition. This hesitation directly hampers market growth by slowing the adoption rate of delivery systems such as insulin pens and pumps. Furthermore, for patients who do commence therapy, the discomfort associated with repeated needle insertion often results in skipped doses and poor compliance, which reduces the recurring consumption of essential consumables and limits the effective penetration of these medical devices.

The impact of this aversion is particularly detrimental given the vast scale of the population requiring glycemic management. The market potential is theoretically high, yet the conversion of diagnosed patients into consistent users of delivery devices is obstructed by these behavioral barriers. According to the International Diabetes Federation, in 2025, the total number of adults living with diabetes in the United Arab Emirates was estimated to reach approximately 1.27 million. This substantial figure highlights a massive addressable market that remains under-penetrated; as long as the fear of injection persists as a deterrent, a significant portion of these 1.27 million individuals may minimize their engagement with insulin delivery technologies, thereby constraining overall market revenue and volume growth.

Key Market Trends

The Integration of Hybrid Closed-Loop Delivery Systems represents a transformative shift in the UAE market, moving beyond simple insulin administration to automated, algorithm-driven glycemic control. These systems, often termed "artificial pancreases," autonomously adjust basal insulin delivery based on real-time sensor data, significantly reducing the burden of self-management for patients with Type 1 diabetes. This technological evolution is being rapidly embraced by national healthcare providers seeking to improve clinical outcomes and reduce long-term complications. According to Emirates Health Services, March 2025, the utilization rate of AI-driven insulin pumps within their network achieved an impressive 87%, highlighting the robust acceptance and successful deployment of these sophisticated automated delivery technologies across the public health sector.

Concurrently, the Rapid Adoption of Smart Connected Insulin Pens is accelerating, driven by the need to digitize injection data and integrate it into the broader diabetes management ecosystem. This trend addresses the adherence challenge by enabling devices to automatically record dosing timing and volume, which is then synchronized with mobile applications for review by patients and clinicians. The demand for these advanced peripherals is reflected in the surging procurement activities of major healthcare conglomerates in the region. According to PureHealth, February 2025, their procurement and supply segment, which actively expanded its medical device and diabetes divisions, recorded a substantial 27% year-on-year revenue increase, underscoring the growing market appetite for modern, tech-enabled administration solutions.

Segmental Insights

The Homecare segment is emerging as the fastest growing category within the UAE Insulin Delivery Devices Market. This expansion is driven by the rising incidence of diabetes and a strategic shift towards patient self-management to alleviate the burden on clinical facilities. The Ministry of Health and Prevention (MoHAP) supports initiatives that encourage individuals to monitor and administer treatment independently, thereby reducing the necessity for frequent hospital visits. Consequently, the adoption of convenient delivery systems has increased significantly among patients, positioning the homecare sector for sustained development.

Regional Insights

Abu Dhabi maintains a leading position in the UAE insulin delivery devices market, supported by substantial investment in healthcare infrastructure and chronic disease management. The Department of Health – Abu Dhabi enforces regulatory frameworks that prioritize diabetes care, ensuring the consistent availability of essential medical tools. Furthermore, the region benefits from a comprehensive mandatory health insurance model that improves patient access to insulin pens and pumps by reducing financial barriers. This favorable reimbursement environment, combined with the strategic expansion of specialized treatment centers, drives the sustained demand for diabetes management products within the emirate.

Recent Developments

• In November 2025, Roche Diabetes Care announced the availability of its AI-enabled continuous glucose monitoring (CGM) solution in the Middle East, with a rollout scheduled for the United Arab Emirates in the near future. The system features predictive algorithms capable of forecasting glucose levels up to two hours in advance and detecting potential nighttime hypoglycemia, empowering users to take proactive therapy adjustments. This launch represented a major advancement in the region's diabetes care landscape, offering patients and healthcare providers enhanced digital tools for more precise and personalized glucose management.
• In April 2025, Gulf Pharmaceutical Industries (Julphar) celebrated the official launch of its newly developed and locally manufactured portfolio of insulin analogues at an event attended by healthcare professionals. This milestone included the introduction of rapid-acting and long-acting insulin formulations designed to meet the diverse needs of patients in the UAE and the wider MENA region. The launch underscored the company's commitment to strengthening the local pharmaceutical supply chain and providing high-quality, domestically produced diabetes management solutions to reduce reliance on imports.
• In March 2025, Insulet Corporation revealed its plans to expand the availability of its flagship automated insulin delivery system to five additional markets, including the United Arab Emirates. The announcement detailed that the tubeless, waterproof pod system, which integrates with continuous glucose monitors to automate insulin delivery, would soon be accessible to patients in the region. This expansion marked a significant step in the company's global strategy to provide advanced, wearable diabetes management technology to a broader patient base in the Middle East, reducing the burden of multiple daily injections.
• In May 2024, the Vice President of a leading Danish healthcare company in the UAE announced the launch of a new GLP-1 receptor agonist medication specifically licensed for weight management. This strategic introduction aimed to alleviate the widespread off-label use of the company’s primary diabetes treatment, which had caused significant shortages for diabetic patients in the region. By providing a dedicated alternative for obesity treatment, the company intended to stabilize the supply chain and ensure that individuals with diabetes could access their essential insulin delivery pens and medications without interruption.

Key Market Players

• Novo Nordisk A/S
• Medtronic Meta FZ‑LLC
• Sanofi S.A.
• Abbott Laboratories, S.A.
• Roche Diabetes Care Middle East
• Eli Lilly and Company
• Wockhardt Ltd.
• Julphar Pharmaceuticals
• Nipro Middle East FZE
• B. Braun Medical Gulf FZ‑LLC

By Product Type	By Distribution Channel	By End User	By Region
Pens Pumps Pen Needles	Hospital Pharmacies Retail Pharmacies Online Others	Hospitals & Clinics Homecare Others	Dubai Abu Dhabi Sharjah Rest of UAE

Report Scope:

In this report, the UAE Insulin Delivery Devices Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• UAE Insulin Delivery Devices Market, By Product Type:

• Pens
• Pumps
• Pen Needles

• UAE Insulin Delivery Devices Market, By Distribution Channel:

• Hospital Pharmacies
• Retail Pharmacies
• Online
• Others

• UAE Insulin Delivery Devices Market, By End User:

• Hospitals & Clinics
• Homecare
• Others

• UAE Insulin Delivery Devices Market, By Region:

• Dubai
• Abu Dhabi
• Sharjah
• Rest of UAE